Cancer markers previously used to detect MRD are predominantly methylated in epithelial and intermediate cell lines, with RASSF1A, TWIST1, and RARβ methylation covering more of the epithelial–mesenchymal spectrum in the cell line panel. Here, TWIST1 is linked to cancer.